<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39610330</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.</ArticleTitle><Pagination><StartPage>e70091</StartPage><MedlinePgn>e70091</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.70091</ELocationID><Abstract><AbstractText>Long coronavirus disease 2019 (COVID) (LC) symptoms including pain and autonomic dysfunction are in some patients associated with small-fiber neuropathy (SFN). The pathomechanisms underlying SFN are mostly unclear. Natural killer (NK) cells play a crucial role in immune regulation, viral clearance and nerve metabolism. The aim of this study was to identify associations between development of small-fiber dysfunction dependent and independent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and human genetic markers associated with specific NK cell functions. The genetic markers assessed in all cohorts included: FCGR3A, IGHG1, HLA-E, NKG2C, and rs9916629. Genotyping was performed using TaqMan assays, Sanger sequencing and touchdown polymerase chain reaction. We assessed human cytomegalovirus (HCMV) IgG serostatus in all participants, and screened for anti-neuronal, anti-glial and anti-ganglioside autoantibodies in both patient cohorts. We included 50 LC patients with newly-emerged symptoms of small-fiber dysfunction after SARS-CoV-2 infection, 27 prepandemic SFN patients and 320 control persons. Markers associated with low NKG2C response, that is, deletion of the NKG2C gene and lack of prior HCMV infection (IgG seronegativity), occurred significantly more frequently in prepandemic SFN patients compared to LC patients and controls (p&#x2009;=&#x2009;0.0109 and 0.0005, respectively). In conclusion, markers of impaired NKG2C pathways are associated with prepandemic SFN, but not with Long COVID-associated small-fiber dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Graninger</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2152-7798</Identifier><AffiliationInfo><Affiliation>Center for Virology, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endmayr</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;hner</LastName><ForeName>Laura M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Center for Virology, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Center for Virology, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rommer</LastName><ForeName>Paulus</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klotz</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vietzen</LastName><ForeName>Hannes</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3993-6538</Identifier><AffiliationInfo><Affiliation>Center for Virology, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;ftberger</LastName><ForeName>Romana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puchhammer-St&#xf6;ckl</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Virology, Medical University of Vienna, Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>The study was supported by Medical and Scientific Fund of the Mayor of the Federal Capital of Vienna, Austria and Center for Virology, Medical University of Vienna, Austria.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055654">NK Cell Lectin-Like Receptor Subfamily C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017452">Receptors, IgG</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496124">FCGR3A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527059">KLRC2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="Y">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071075" MajorTopicYN="Y">Small Fiber Neuropathy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055654" MajorTopicYN="N">NK Cell Lectin-Like Receptor Subfamily C</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017452" MajorTopicYN="N">Receptors, IgG</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NK cell</Keyword><Keyword MajorTopicYN="N">NKG2C</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">small fiber neuropathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39610330</ArticleId><ArticleId IdType="doi">10.1002/jmv.70091</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. C. Dalakas, &#x201c;Post&#x2010;Covid Small Fiber Neuropathy, Implications of Innate Immunity, and Challenges on IVIG Therapy,&#x201d; Neurology Neuroimmunology &amp; Neuroinflammation 11, no. 3 (2024): e200248.</Citation></Reference><Reference><Citation>M. Sivan and S. Taylor, &#x201c;NICE Guideline on Long Covid,&#x201d; BMJ 371 (2020): m4938.</Citation></Reference><Reference><Citation>A. L. Oaklander and M. Nolano, &#x201c;Scientific Advances in and Clinical Approaches to Small&#x2010;Fiber Polyneuropathy: A Review,&#x201d; JAMA Neurology 76, no. 10 (2019): 1240&#x2013;1251.</Citation></Reference><Reference><Citation>A. G. Freud, B. L. Mundy&#x2010;Bosse, J. Yu, and M. A. Caligiuri, &#x201c;The Broad Spectrum of Human Natural Killer Cell Diversity,&#x201d; Immunity 47, no. 5 (2017): 820&#x2013;833.</Citation></Reference><Reference><Citation>A. J. Davies, S. Rinaldi, M. Costigan, and S. B. Oh, &#x201c;Cytotoxic Immunity in Peripheral Nerve Injury and Pain,&#x201d; Frontiers in Neuroscience 14 (2020): 142.</Citation></Reference><Reference><Citation>M. Moraru, L. E. Black, A. Muntasell, et al., &#x201c;NK Cell and Ig Interplay in Defense Against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody&#x2010;Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation,&#x201d; The Journal of Immunology 195, no. 4 (2015): 1676&#x2013;1684.</Citation></Reference><Reference><Citation>L. Kanevskiy, S. Erokhina, P. Kobyzeva, M. Streltsova, A. Sapozhnikov, and E. Kovalenko, &#x201c;Dimorphism of HLA&#x2010;E and Its Disease Association,&#x201d; International Journal of Molecular Sciences 20, no. 21 (2019): 5496.</Citation></Reference><Reference><Citation>H. Vietzen, A. Zoufaly, M. Traugott, J. Aberle, S. W. Aberle, and E. Puchhammer&#x2010;St&#xf6;ckl, &#x201c;Deletion of the NKG2C Receptor Encoding KLRC2 Gene and HLA&#x2010;E Variants Are Risk Factors for Severe Covid&#x2010;19,&#x201d; Genetics in Medicine 23, no. 5 (2021): 963&#x2013;967.</Citation></Reference><Reference><Citation>H. Vietzen, S. M. Berger, L. M. K&#xfc;hner, et al., &#x201c;Ineffective Control of Epstein&#x2010;Barr&#x2010;Virus&#x2010;Induced Autoimmunity Increases the Risk for Multiple Sclerosis,&#x201d; Cell 186 (2023): 5705&#x2013;5718.e13.</Citation></Reference><Reference><Citation>U. C. Kucuksezer, E. Aktas Cetin, F. Esen, et al., &#x201c;The Role of Natural Killer Cells in Autoimmune Diseases,&#x201d; Frontiers in Immunology 12 (2021): 622306.</Citation></Reference><Reference><Citation>H. Vietzen, P. L. Furlano, M. Traugott, et al., &#x201c;The Natural Killer Cell&#x2010;Associated rs9916629&#x2010;C Allele Is a Novel Genetic Risk Factor for Fatal Covid&#x2010;19,&#x201d; Journal of Medical Virology 95, no. 1 (2023): e28404.</Citation></Reference><Reference><Citation>V. Provitera, C. H. Gibbons, G. Wendelschafer&#x2010;Crabb, et al., &#x201c;A Multi&#x2010;Center, Multinational Age&#x2010; and Gender&#x2010;Adjusted Normative Dataset for Immunofluorescent Intraepidermal Nerve Fiber Density at the Distal Leg,&#x201d; European Journal of Neurology 23, no. 2 (2016): 333&#x2013;338.</Citation></Reference><Reference><Citation>J. C. McArthur, E. A. Stocks, P. Hauer, D. R. Cornblath, and J. W. Griffin, &#x201c;Epidermal Nerve Fiber Density: Normative Reference Range and Diagnostic Efficiency,&#x201d; Archives of Neurology 55, no. 12 (1998): 1513&#x2013;1520.</Citation></Reference><Reference><Citation>H. Vietzen, B. D&#xf6;hler, T. H. Tran, et al., &#x201c;Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome,&#x201d; Frontiers in Immunology 13 (2022): 829228.</Citation></Reference><Reference><Citation>B. Simon, L. Weseslindtner, I. G&#xf6;rzer, et al., &#x201c;Subclass&#x2010;Specific Antibody Responses to Human Cytomegalovirus in Lung Transplant Recipients and Their Association With Constant Heavy Immunoglobulin G Chain Polymorphism and Virus Replication,&#x201d; The Journal of Heart and Lung Transplantation 35, no. 3 (2016): 370&#x2013;377.</Citation></Reference><Reference><Citation>M. M. Paquay, J. Schellekens, and M. G. J. Tilanus, &#x201c;A High&#x2010;Throughput Taqman Approach for the Discrimination of HLA&#x2010;E Alleles,&#x201d; Tissue Antigens 74, no. 6 (2009): 514&#x2013;519.</Citation></Reference><Reference><Citation>D. Redondo&#x2010;Pach&#xf3;n, M. Crespo, J. Y&#xe9;lamos, et al., &#x201c;Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients,&#x201d; The Journal of Immunology 198, no. 1 (2017): 94&#x2013;101.</Citation></Reference><Reference><Citation>C. A. Pardo, J. C. McArthur, and J. W. Griffin, &#x201c;HIV Neuropathy: Insights in the Pathology of HIV Peripheral Nerve Disease,&#x201d; Journal of the Peripheral Nervous System 6, no. 1 (2001): 21&#x2013;27.</Citation></Reference><Reference><Citation>T. Androutsakos, I. Tsantzali, D. S. Karagiannakis, et al., &#x201c;Peripheral Neuropathy in Patients With Hepatitis C Infection&#x2010;Reversibility after HCV Eradication: A Single Center Study,&#x201d; Viruses 16, no. 4 (2024): 522.</Citation></Reference><Reference><Citation>J. A. Goodfellow and H. J. Willison, &#x201c;Gangliosides and Autoimmune Peripheral Nerve Diseases,&#x201d; Progress in Molecular Biology and Translational Science 156 (2018): 355&#x2013;382.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>